Table of Contents
SRX Medicine
Volume 2010, Article ID 812304, 8 pages
http://dx.doi.org/10.3814/2010/812304
Review Article

Is Absolute Lymphocyte Count Just Another Prognostic Factor in Cancer?

Department of Medicine, Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA

Received 24 November 2009; Revised 12 January 2010; Accepted 27 January 2010

Copyright © 2010 Luis F. Porrata and Svetomir N. Markovic. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Ehrlich, “Ueber den jetzigen Stand der Karzinomforschung,” Nederlands Tijdschrift voor Geneeskunde, vol. 5, pp. 273–290, 1909. View at Google Scholar
  2. M. Burnet, “Cancer; a biological approach. I. The processes of control,” British Medical Journal, vol. 1, no. 5022, pp. 779–786, 1957. View at Google Scholar
  3. M. S. Block and S. N. Markovic, “The tumor/immune interface: clinical evidence of cancer immunosurveillance, immunoediting and immunosubversion,” American Journal of Immunology, vol. 5, no. 1, pp. 29–49, 2009. View at Google Scholar
  4. Y. Oki, K. Yamamoto, H. Kato et al., “Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab,” European Journal of Haematology, vol. 81, no. 6, pp. 448–453, 2008. View at Publisher · View at Google Scholar · View at PubMed
  5. M. C. Cox, I. Nofroni, L. Ruco et al., “Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma,” Leukemia and Lymphoma, vol. 49, no. 9, pp. 1745–1751, 2008. View at Publisher · View at Google Scholar · View at PubMed
  6. M. C. Cox, I. Nofroni, G. Laverde et al., “Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma,” British Journal of Haematology, vol. 141, no. 2, pp. 265–268, 2008. View at Publisher · View at Google Scholar · View at PubMed
  7. M. Siddiqui, K. Ristow, S. N. Markovic et al., “Absolute lymphocyte count predicts overall survival in follicular lymphomas,” British Journal of Haematology, vol. 134, no. 6, pp. 596–601, 2006. View at Publisher · View at Google Scholar · View at PubMed
  8. I. Ray-Coquard, C. Cropet, M. Van Glabbeke et al., “Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas,” Cancer Research, vol. 69, no. 13, pp. 5383–5391, 2009. View at Publisher · View at Google Scholar
  9. H. Ege, M. A. Gertz, S. N. Markovic et al., “Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study,” British Journal of Haematology, vol. 141, no. 6, pp. 792–798, 2008. View at Publisher · View at Google Scholar · View at PubMed
  10. N. L. Jacobs, S. G. Holtan, L. F. Porrata, S. N. Markovic, A. Tefferi, and D. P. Steensma, “Low absolute lymphocyte count (ALC) at diagnosis is an IPSS-independent predictor of poorer survival in myelodysplastic syndrome (MDS),” Blood, vol. 112, 2008, abstract 3633. View at Google Scholar
  11. A. E. Papatestas, G. J. Lesnick, G. Genkins, and A. H. Aufses Jr., “The prognostic significance of peripheral lymphocyte counts in patients with breast carcinoma,” Cancer, vol. 37, no. 1, pp. 164–168, 1976. View at Google Scholar
  12. J. S. Blake-Mortimer, S. E. Sephton, R. W. Carlson, D. Stites, and D. Spiegel, “Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancer,” Breast Journal, vol. 10, no. 3, pp. 195–199, 2004. View at Publisher · View at Google Scholar · View at PubMed
  13. P. Fogar, C. Sperti, D. Basso et al., “Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome,” Pancreas, vol. 32, no. 1, pp. 22–28, 2006. View at Google Scholar
  14. A. Fukunaga, M. Miyamoto, Y. Cho et al., “CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma,” Pancreas, vol. 28, no. 1, pp. 26–31, 2004. View at Google Scholar
  15. A. Riesco, “Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils,” Cancer, vol. 25, no. 1, pp. 135–140, 1970. View at Google Scholar
  16. Y. T. N. Lee, “Peripheral lymphocyte count and subpopulations of T and B lymphocytes in benign and malignant diseases,” Surgery, Gynecology and Obstetrics, vol. 144, no. 3, pp. 435–450, 1977. View at Google Scholar
  17. F. Marti, N. Pardo, M. Peiro et al., “Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation,” Experimental Hematology, vol. 23, no. 14, pp. 1445–1452, 1995. View at Google Scholar
  18. D. Behl, L. F. Porrata, S. N. Markovic et al., “Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia,” Leukemia, vol. 20, no. 1, pp. 29–34, 2006. View at Publisher · View at Google Scholar · View at PubMed
  19. G. De Angulo, C. Yuen, S. L. Palla, P. M. Anderson, and P. A. Zweidler-McKay, “Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies,” Cancer, vol. 112, no. 2, pp. 407–415, 2008. View at Publisher · View at Google Scholar · View at PubMed
  20. P. Lissoni, F. Brivio, L. Fumagalli et al., “Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastic solid tumors,” International Journal of Biological Markers, vol. 19, no. 2, pp. 135–140, 2004. View at Google Scholar
  21. G. De Angulo, M. Hernandez, J. Morales-Arias et al., “Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma,” Journal of Pediatric Hematology/Oncology, vol. 29, no. 1, pp. 48–52, 2007. View at Publisher · View at Google Scholar · View at PubMed
  22. S. G. DuBois, K. Elterman, and H. E. Grier, “Early lymphocyte recovery in Ewing sarcoma,” Journal of Pediatric Hematology/Oncology, vol. 29, no. 5, pp. 351–352, 2007. View at Publisher · View at Google Scholar · View at PubMed
  23. L. F. Porrata, K. Ristow, T. M. Habermann, T. E. Witzig, D. J. Inwards, and S. N. Markovic, “Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma,” American Journal of Hematology, vol. 84, no. 2, pp. 93–97, 2009. View at Publisher · View at Google Scholar · View at PubMed
  24. D. R. Choi, D. H. Yoon, H. J. Ahn et al., “Significance of absolute lymphocyte count at relapse as a prognostic factor in patients with T-cell non-Hodgkin's lymphoma,” Blood, vol. 144, 2009, abstract 2939. View at Google Scholar
  25. I. Ray-Coquard, H. Ghesquière, T. Bachelot et al., “Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas,” British Journal of Cancer, vol. 85, no. 6, pp. 816–822, 2001. View at Publisher · View at Google Scholar · View at PubMed
  26. A. J. Barrett and B. N. Savani, “Does chemotherapy modify the immune surveillance of hematological malignancies?” Leukemia, vol. 23, no. 1, pp. 53–58, 2009. View at Publisher · View at Google Scholar · View at PubMed
  27. D. Decaudin, G. Des Guetz, C. Mathiot et al., “Absolute lymphocyte count as a predictive factor for response to monoclonal anti-CD20 antibody therapy,” Annals of Oncology, vol. 14, no. 1, pp. 171–172, 2003. View at Publisher · View at Google Scholar
  28. D. Behl, K. Ristow, S. N. Markovic et al., “Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas,” British Journal of Haematology, vol. 137, no. 5, pp. 409–415, 2007. View at Publisher · View at Google Scholar · View at PubMed
  29. T. E. Witzig, “Radioimmunotherapy for B-cell non-Hodgkin lymphoma,” Best Practice and Research: Clinical Haematology, vol. 19, no. 4, pp. 655–668, 2006. View at Publisher · View at Google Scholar · View at PubMed
  30. L. F. Porrata, K. Ristow, T. E. Witzig et al., “Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas,” Leukemia, vol. 21, no. 12, pp. 2554–2556, 2007. View at Publisher · View at Google Scholar · View at PubMed
  31. D. Zhu, L. G. Corral, Y. W. Fleming, and B. Stein, “Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation,” Cancer Immunology, Immunotherapy, vol. 57, no. 12, pp. 1849–1859, 2008. View at Publisher · View at Google Scholar · View at PubMed
  32. T. E. Witzig, C. B. Reeder, J. Polikoff et al., “Initial results from an international study in relapse/refractory aggressive non-Hodgkin's lymphoma to confirm the activity, safety and criteria for predicting response to lenalidomide monotherapy,” Blood, vol. 110, 2007, abstract 2572. View at Google Scholar
  33. P. H. Wiernik, I. S. Lossos, J. M. Tuscano et al., “Lenalidomide response in relapsed/refractory aggressive non-Hodgkin's lymphoma is related to tumor burden and time from rituximab treatment,” Blood, vol. 110, 2007, abstract 2565. View at Google Scholar
  34. S. Mustjoki, T. Lundán, S. Knuutila, and K. Porkka, “Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia,” Leukemia, vol. 21, no. 11, pp. 2363–2368, 2007. View at Publisher · View at Google Scholar · View at PubMed
  35. D. W. H. Barnes, M. J. Corp, J. F. Loutit, and F. E. Neal, “Treatment of murine leukemia with X-rays and homologous bone marrow. Preliminary communication,” British Medical Journal, vol. 2, pp. 626–627, 1956. View at Google Scholar
  36. L. F. Porrata and S. N. Markovic, “Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation,” Clinical and Experimental Medicine, vol. 4, no. 2, pp. 78–85, 2004. View at Publisher · View at Google Scholar
  37. R. Powles, S. Singhal, J. Treleaven, S. Kulkarni, C. Horton, and J. Mehta, “Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation,” Blood, vol. 91, no. 9, pp. 3481–3486, 1998. View at Google Scholar
  38. Z. S. Pavletic, S. S. Joshi, S. J. Pirruccello et al., “Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies,” Bone Marrow Transplantation, vol. 21, no. 1, pp. 33–41, 1998. View at Google Scholar
  39. L. F. Porrata, M. A. Gertz, D. J. Inwards et al., “Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma,” Blood, vol. 98, no. 3, pp. 579–585, 2001. View at Publisher · View at Google Scholar
  40. L. F. Porrata, M. R. Litzow, A. Tefferi et al., “Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia,” Leukemia, vol. 16, no. 7, pp. 1311–1318, 2002. View at Publisher · View at Google Scholar · View at PubMed
  41. L. F. Porrata, D. J. Inwards, I. N. Micallef, S. M. Ansell, S. M. Geyer, and S. N. Markovic, “Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease,” British Journal of Haematology, vol. 117, no. 3, pp. 629–633, 2002. View at Publisher · View at Google Scholar
  42. L. F. Porrata, M. A. Gertz, M. R. Litzow et al., “Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis,” Clinical Cancer Research, vol. 11, no. 3, pp. 1210–1218, 2005. View at Google Scholar
  43. C. Joao, L. F. Porrata, D. J. Inwards et al., “Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma,” Bone Marrow Transplantation, vol. 37, no. 9, pp. 865–871, 2006. View at Publisher · View at Google Scholar · View at PubMed
  44. L. F. Porrata, J. N. Ingle, M. R. Litzow, S. Geyer, and S. N. Markovic, “Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer,” Bone Marrow Transplantation, vol. 28, no. 9, pp. 865–871, 2001. View at Publisher · View at Google Scholar · View at PubMed
  45. G. Ferrandina, L. Pierelli, A. Perillo et al., “Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support: clinical implications,” Clinical Cancer Research, vol. 9, no. 10, pp. 195–200, 2003. View at Google Scholar
  46. M. R. Boulassel, A. L. Herr, M. D. deB Edwardes et al., “Early lymphocyte recovery following autologous peripheral stem cell transplantation is associated with better survival in younger patients with lymphoproliferative disorders,” Hematology, vol. 11, no. 3, pp. 165–170, 2006. View at Publisher · View at Google Scholar · View at PubMed
  47. H. Kim, H.-J. Sohn, S. Kim, J.-S. Lee, W.-K. Kim, and C. Suh, “Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma,” Bone Marrow Transplantation, vol. 37, no. 11, pp. 1037–1042, 2006. View at Publisher · View at Google Scholar · View at PubMed
  48. Y. Nieto, E. J. Shpall, I. K. McNiece et al., “Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant,” Clinical Cancer Research, vol. 10, no. 15, pp. 5076–5086, 2004. View at Publisher · View at Google Scholar · View at PubMed
  49. H. Kim, H.-J. Sohn, S.-E. Kim et al., “Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma,” Bone Marrow Transplantation, vol. 34, no. 1, pp. 43–49, 2004. View at Publisher · View at Google Scholar · View at PubMed
  50. L. N. Gordan, M. W. Sugrue, J. W. Lynch, K. D. Williams, S. A. Khan, and J. S. Moreb, “Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma,” Bone Marrow Transplantation, vol. 31, no. 11, pp. 1009–1013, 2003. View at Publisher · View at Google Scholar · View at PubMed
  51. L. F. Porrata, D. J. Inwards, S. M. Ansell et al., “Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study,” Biology of Blood and Marrow Transplantation, vol. 14, no. 7, pp. 807–816, 2008. View at Publisher · View at Google Scholar · View at PubMed
  52. A. Plonquet, C. Haioun, J.-P. Jais et al., “Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma,” Annals of Oncology, vol. 18, no. 7, pp. 1209–1215, 2007. View at Publisher · View at Google Scholar · View at PubMed
  53. B.-Q. Zhu, S.-W. Ju, and Y.-Q. Shu, “CD137 enhances cytotoxicity of CD3+CD56+ cells and their capacities to induce CD4+ Th1 responses,” Biomedicine and Pharmacotherapy, vol. 63, no. 7, pp. 509–516, 2009. View at Publisher · View at Google Scholar
  54. R. Houot, M. J. Goldstein, H. E. Kohrt et al., “Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion,” Blood, vol. 114, no. 16, pp. 3431–3438, 2009. View at Publisher · View at Google Scholar · View at PubMed
  55. S. Mittal, N. A. Marshall, L. Duncan, D. J. Culligan, R. N. Barker, and M. A. Vickers, “Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma,” Blood, vol. 111, no. 11, pp. 5359–5370, 2008. View at Publisher · View at Google Scholar · View at PubMed
  56. Z. Z. Yang and S. M. Ansell, “The role of T-reg cells in the cancer immunological response,” American Journal of Immunology, vol. 5, no. 10, pp. 17–28, 2009. View at Google Scholar
  57. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at PubMed
  58. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at PubMed
  59. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at PubMed
  60. S. Teramukai, T. Kitano, Y. Kishida et al., “Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03,” European Journal of Cancer, vol. 45, no. 11, pp. 1950–1958, 2009. View at Publisher · View at Google Scholar
  61. J. Atzpodien, P. Royston, T. Wandert et al., “Metastatic renal carcinoma comprehensive prognostic system,” British Journal of Cancer, vol. 88, no. 3, pp. 348–353, 2003. View at Publisher · View at Google Scholar · View at PubMed
  62. H. Schmidt, S. Suciu, C. J. A. Punt et al., “Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer stage IV melanoma: results of the EORTC 18951 biochemotherapy trial,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1562–1569, 2007. View at Publisher · View at Google Scholar · View at PubMed
  63. K. M. Sarraf, E. Belcher, E. Raevsky, A. G. Nicholson, P. Goldstraw, and E. Lim, “Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer,” Journal of Thoracic and Cardiovascular Surgery, vol. 137, no. 2, pp. 425–428, 2009. View at Publisher · View at Google Scholar
  64. Y. Nakahara, Y. Mochiduki, Y. Miyamoto, Y. Nakahara, and Y. Katsura, “Prognostic significance of the lymphocyte-to-neutrophil ratio in percutaneous fine-needle aspiration biopsy specimens of advanced nonsmall cell lung carcinoma,” Cancer, vol. 104, no. 6, pp. 1271–1280, 2005. View at Publisher · View at Google Scholar · View at PubMed
  65. F. J. Esteva and L. Pusztai, “Optimizing outcomes in HER2-positive breast cancer: the molecular rationale,” Oncology, vol. 19, no. 13, supplement 5, pp. 5–16, 2005. View at Google Scholar
  66. L. F. Porrata, “Clinical evidence of autologous graft versus tumor effect,” American Journal of Immunology, vol. 5, no. 1, pp. 1–7, 2009. View at Google Scholar
  67. C. Joao, L. F. Porrata, E. A. Burgstaler et al., “Immunologic autograft engineering by manipulation of apheresis machine collection settings,” Biology of Blood and Marrow Transplantation, vol. 12, no. 2, supplement 1, p. 105, 2006, abstract 298. View at Google Scholar